Ovid Therapeutics
OVID
47 hedge funds and large institutions have $16.5M invested in Ovid Therapeutics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 11 closing their positions.
2.29% less ownership
Funds ownership: 30.02% → 27.73% (-2.3%)
4% less funds holding
Funds holding: 49 → 47 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
61% less capital invested
Capital invested by funds: $41.9M → $16.5M (-$25.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.3M |
| 2 |
CI
Cowen Inc
New York
|
+$656K |
| 3 |
JP Morgan Chase
New York
|
+$363K |
| 4 |
Renaissance Technologies
New York
|
+$251K |
| 5 |
Two Sigma Investments
New York
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.76M |
| 2 |
O
OppenheimerFunds
New York
|
-$2.41M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$1.26M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$896K |
OVID Hedge Fund Activity: Q4 2018 in Review
47 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2018, worth a combined $16.5M — down 61% from $41.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OVID and 9 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 13 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $7.3M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.76M sold.
- 47 institutional investors held Ovid Therapeutics (OVID) as of Q4 2018, down from 49 in Q3 2018.
- Funds reported $16.5M of Ovid Therapeutics stock for Q4 2018, down 61% quarter-over-quarter.
- 9 funds opened new Ovid Therapeutics positions in Q4 2018 and 11 closed out, a net change of -2 holders.
- The largest Ovid Therapeutics buyer in Q4 2018 was Armistice Capital, an estimated $7.3M added.
- The largest Ovid Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $5.76M sold.
Based on aggregated 13F filings for Q4 2018.